- 2025-07-10
- Frontiers in pharmacology 16
- Peng Dai
- Lingyu Xu
- Peng Zhang
- Zheng Liang
- Yunhang Chu
- Ziqiao Yu
- Lin Cao
- Peng Sun
- Xia Li
Study Design
- Type
- Systematic Review
- Sample size
- n = 23
- Population
- rodent epilepsy models
- Methods
- meta-analysis of 23 eligible animal studies identified by searching eight databases up to March 2025; SYRCLE's risk of bias tool used; meta-analysis performed using Review Manager 5.4 and Stata 18
Objective
The purpose of this study is to systematically evaluate the therapeutic effect of curcumin on rodent epilepsy models through a meta-analysis of multiple animal experiments. It will also explore its potential mechanism of anti-oxidative stress and anti-inflammation to provide a theoretical basis for the application of curcumin in the clinical treatment of epilepsy.Methods
A total of 23 eligible animal studies were identified by searching eight databases (up to March 2025), including PubMed, Embase, Web of Science, Cochrane Library, and CNKI, Wan Fang, VIP, CBM. SYRCLE's risk of bias tool was used to assess the quality of the literature, and Meta-analysis was performed using Review Manager 5.4 and Stata 18 software. Primary outcome measures included epilepsy latency, Morris water maze escape latency, oxidative stress markers (MDA, GSH, SOD), inflammatory factors (IL-1β, TNF-α), and Glial fibrillary acidic protein (GFAP).Results
Meta-analysis showed that the curcumin intervention group significantly extended the epilepsy latency (SMD = 1.85, 95% CI = 1.05-2.64, P < 0.00001) and shortened the water maze escape latency (SMD = -1.69, 95% CI = -2.23-1.16, P < 0.00001). In terms of antioxidant indicators, curcumin significantly decreased MDA levels (SMD = -3.50, P < 0.00001) and increased GSH (SMD = 2.87, P < 0.00001) and SOD (SMD = 2.42, P < 0.00001). The anti-inflammatory results showed that the levels of IL-1β (SMD = -1.73, P = 0.04) and TNF-α (SMD = -1.65, P < 0.00001) were significantly decreased, and the levels of GFAP-positive cells were decreased (SMD = -1.72, P = 0.05). Subgroup analysis showed that medium and high doses (100-299 mg/kg and ≥300 mg/kg) of curcumin were more stable, but the low dose group (<100 mg/kg) did not conduct in-depth analysis due to insufficient sample size of individual indicators. Sensitivity analysis and funnel plots suggest robust results, but some publication bias exists.Conclusion
Curcumin can effectively improve epileptic seizures and cognitive dysfunction in epileptic rodents through the dual mechanisms of antioxidative stress (inhibiting lipid peroxidation and enhancing antioxidant enzyme activity) and anti-inflammatory (reducing the release of pro-inflammatory factors and inhibiting glial cell activation). However, species differences and potential publication bias have certain effects on the results, and high-quality clinical studies can be carried out in the future to verify their clinical application value.